Through its S2B2C business model, 111 leverages technology to enable businesses to serve customers better across its omni-channel platform. In 2024, the company achieved 14.40 billion RMB in revenue and achieved its first-ever annual operating profit.
Cyborg Score Rationale
Revenue declined 3.66% to 14.40 billion RMB in 2024, though losses improved significantly by 83.51%. Volatility has increased from 12% to 20% over the past year, indicating market uncertainty. The company has achieved profitability momentum but faces near-term volatility.
Top Insights
Achieved first-ever annual operating profit in 2024 with operating expenses decreasing 230 basis points year-over-year
Offers supply chain integration services and operates 1 Pharmacy wholesale and 1 Medicine Marketplace online retail channels
Stock price rose 212.11% from December 31, 2025 through early 2026, indicating strong recent momentum
Operates the largest virtual pharmacy network in China, enabling offline pharmacies to leverage cloud-based services
Named Competitors
Online Healthcare Platform — E-commerce and online healthcare services in China
Digital Pharmacy Network — Integrated digital health ecosystem and online pharmacy services
Healthcare E-commerce — Digital healthcare services and medical e-commerce
Recent Developments
(Mar 2025) Achieved first-ever annual operating profit in 2024 with improved bottom line